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CAM is widely used in sport, often by elite athletes. One example is Michael Phelps’ use of 
‘cupping’ during the 2016 Olympics. Evidence for the effectiveness of CAM in sport has been 
reported in some work, but more studies have reported CAM outcomes as no better than 
placebo. The link between CAM and the placebo effect has been made explicit by health 
agencies (1) and scientists. (2) As a consequence, where credible causal mechanisms for 
apparent therapeutic effects are absent, placebo effects are often assumed. 
 
The placebo effect was historically considered a non-specific phenomenon, but recent 
studies indicate numerous discrete placebo effects operating via dopamine,(3) opioid,(4) 
and cannabinoid(5) neurotransmission. For example, placebo analgesia following 
preconditioning with morphine is blocked by the antagonist naloxone,  but analgesia 
conditioned using a non-opioid drug was naloxone insensitive. Likewise, the cannabinoid 
receptor antagonist rimonabant had no effect on opioid-induced placebo analgesia following 
preconditioning with morphine, but antagonised placebo analgesia following 
preconditioning with the nonopioid NSAID, ketorolac.   
 
Such connections between brain physiology and mechanistic evidence is being used as an 
argument for  CAM. We have been researching the placebo effect in sport for some time (14 
years in the case of the first author). Whilst it is not unusual to be invited to speak at 
scientific conferences or to media on one’s area of expertise, we now receive as many 
invitations to speak on the issue of CAM, and an equal volume of traffic from proponents 
Complementary and alternative medicines (CAM) are treatments for which either 
evidence is lacking, or for which evidence suggests no effect over a placebo treatment. 
When a non-evidence-based treatment is used alongside conventional medicine, it is 
considered "complementary”. When a non evidence-based treatment is used instead 
of conventional medicine, it is considered "alternative". Many forms of CAM have 
origins and/or a history of use beyond evidence-based medicine. Further, many CAM 
treatments are based on principles and/or evidence that are not recognised by the 
majority of independent scientists. When a person uses CAM and experiences an 
improvement in symptoms, this may be due to the placebo effect (1).  
 
  
3 
and/or practitioners of CAM, at times congratulating us for ‘legitimizing’ their product or 
treatment.   
 
We strongly contest this position, and propose five challenges to the idea that placebo 
mechanisms legitimise the use of CAM by clinicians in sports medicine/sports physiotherapy: 
1. Variability: Placebo responding is variable, both between and within athletes.(6) 
Furthermore, most research papers report acute placebo effects, and little is known 
about their stability over time.  
2. Negative placebo effects: The nocebo effect, a negative response related to negative 
expectations, is well documented.(6) Rather than assuming that a CAM treatment 
will either result in a positive effect or no effect, practitioners must consider the 
possibility that administration of a placebo treatment can exert a negative effect. 
3. Failure to adopt a more effective treatment. Athletes are often eager to accept at 
face value treatments that might expedite their return to play.(7)  Consequently, 
patients of practitioners who administer CAM may be denied or choose to forego 
potentially more effective evidence-based treatments.(8) In sport, this might range 
from an athlete not eating sufficient fresh fruit because she is receiving sufficient 
vitamin C through supplements, to choosing CAM as opposed to conventional 
medicine to treat injury or illness.  
4. Ethics of deception: In light of the challenges of points 1 and 2, it is arguably unethical 
to knowingly advocate CAM while also assuming the likely mechanism of effect is the 
placebo. We acknowledge emerging evidence that open label administration of 
placebos can be effective. However, even in such cases, the administration of 
placebos may ultimately be counterproductive. There are serious ethical challenges 
around deception, risk and harm to patients. 
5. Identification of “headroom” mechanisms: The capacity to respond to a placebo is 
evidence of headroom or reserve capacity.(6) Headroom is likely amenable to 
legitimate treatments, both physiological and psychological. Practitioners should 
strive to identify and capitalize on headroom through legitimate, ethical, controllable 
and stable treatments (e.g., optimal nutrition, systematic recovery, and psychological 
skills training).  
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CAM can be effective, but can also be ineffective or even harmful. Evidence is vague in both 
respects, but practitioners and athletes using CAM do not always recognize this. We 
acknowledge the distinction between lack of evidence for an effect, and evidence for the 
lack of an effect. In relation to the former, sports medicine researchers should seek to use 
robust, reliable and, where necessary, innovative methods to establish the efficacy and 
mechanisms of CAM treatments. In relation to the latter, sports medicine practitioners 
should regard non-evidence based treatments with caution, and resist the temptation to rely 
on non-specific effects as a basis for prescription. If a practitioner seeks to use a treatment 
in order to capitalize on the placebo component of that treatment, they should do so 
methodically.(9)  
 
We acknowledge that in sports medicine the outcome is often more important than the 
mechanism. Scientific research on placebo mechanisms has yielded fascinating insights 
suggesting the potential efficacy and mechanisms of belief-based treatments. We anticipate 
that when applied systematically, such research findings enable sports medicine 
practitioners to deliver all treatments – CAM and conventional - more effectively. But such 
use of the placebo component of a treatment does not legitimise CAM per se; whilst it might 
be going too far to suggest that many CAM treatments should be labeled with the statement 
“Caution: This treatment is a placebo, it may work, but it may not, it might even be counter-
productive”, we argue this is most certainly the reality that practitioners should keep in 
mind.  
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